blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2261333

EP2261333 - Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.02.2017
Database last updated on 24.04.2024
Most recent event   Tooltip17.08.2018Lapse of the patent in a contracting state
New state(s): BG		published on 19.09.2018  [2018/38]
Applicant(s)For all designated states
Roche Innovation Center Copenhagen A/S
Fremtidsvej 3
2970 Hørsholm / DK
[2015/50]
Former [2013/40]For all designated states
Stella ApS
Fremtidsvej 3
2970 Hørsholm / DK
Former [2013/03]For all designated states
Santaris Pharma A/S
Fremtidsvej 3
2970 Hørsholm / DK
Former [2010/50]For all designated states
Santaris Pharma A/S
Kogle Allé 6
2970 Hørsholm / DK
Inventor(s)01 / Elmén, Joacim
Sickla Kanalgata 19 A
120 67 Stockholm / SE
02 / Kearney, Phil
2 Wild Street
Picton New South Wales 2571 / AU
03 / Kauppinen, Sakari
Norskekrogen 12
2765 Smoerum / DK
 [2011/40]
Former [2010/50]01 / Elmén, Joacim
Föreningsgaten 61
211 52 Malmoe / SE
02 / Kearney, Phil
2 Wild Street
Picton New South Wales 2571 / AU
03 / Kauppinen, Sakari
Norskekrogen 12
2765 Smoerum / DK
Representative(s)Turner, Mark Frederic Paris, et al
Santaris Pharma A/S
Fremtidsvej 3
2970 Hørsholm / DK
[2013/33]
Former [2010/50]Turner, Mark Frederic Paris
Santaris Pharma A/S Kogle Allé 6
2970 Hørsholm / DK
Application number, filing date10173208.930.03.2007
[2010/50]
Priority number, dateDK2006000047803.04.2006         Original published format: DK 200600478
US20060788995P03.04.2006         Original published format: US 788995 P
DK2006000061501.05.2006         Original published format: DK 200600615
US20060796813P01.05.2006         Original published format: US 796813 P
US20060838710P18.08.2006         Original published format: US 838710 P
DK2006000140130.10.2006         Original published format: DK 200601401
[2010/50]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2261333
Date:15.12.2010
Language:EN
[2010/50]
Type: A3 Search report 
No.:EP2261333
Date:19.03.2014
Language:EN
[2014/12]
Type: B1 Patent specification 
No.:EP2261333
Date:30.03.2016
Language:EN
[2016/13]
Search report(s)(Supplementary) European search report - dispatched on:EP17.02.2014
ClassificationIPC:C12N15/113, A61K31/712, C07H21/00, // A61P3/06, A61P3/10, A61P31/14, A61P35/00, A61P9/10
[2010/50]
CPC:
C12N15/113 (EP,US); A61P1/16 (EP); A61P3/06 (EP);
A61P3/10 (EP); A61P31/12 (EP); A61P31/14 (EP);
A61P35/00 (EP); A61P7/00 (EP); A61P9/10 (EP);
C12N2310/113 (EP,US); C12N2310/321 (EP,US); C12N2310/322 (EP,US);
C12N2310/3231 (EP,US); C12N2310/3515 (EP,US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP,US);
C12N2310/322, C12N2310/3533 (US,EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/13]
Former [2010/50]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Pharmazeutische Zusammensetzung mit Anti-miRNA-Antisense-Oligonukleotiden[2010/50]
English:Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides[2010/50]
French:Composition pharmaceutique comprenant des oligonucléotides antisens anti-ARNmi[2010/50]
Examination procedure19.09.2014Examination requested  [2014/44]
03.11.2014Despatch of a communication from the examining division (Time limit: M06)
07.05.2015Reply to a communication from the examining division
23.10.2015Communication of intention to grant the patent
11.02.2016Fee for grant paid
11.02.2016Fee for publishing/printing paid
11.02.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07722548.0  / EP2007888
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.11.2014
Opposition(s)03.01.2017No opposition filed within time limit [2017/10]
Fees paidRenewal fee
18.08.2010Renewal fee patent year 03
18.08.2010Renewal fee patent year 04
29.03.2011Renewal fee patent year 05
26.03.2012Renewal fee patent year 06
27.03.2013Renewal fee patent year 07
27.03.2014Renewal fee patent year 08
27.03.2015Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.03.2007
AT30.03.2016
BE30.03.2016
BG30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
IE30.03.2016
LT30.03.2016
LU30.03.2016
LV30.03.2016
MC30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
MT31.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
[2018/38]
Former [2018/31]HU30.03.2007
AT30.03.2016
BE30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
IE30.03.2016
LT30.03.2016
LU30.03.2016
LV30.03.2016
MC30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
MT31.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2018/28]HU30.03.2007
AT30.03.2016
BE30.03.2016
CY30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
IE30.03.2016
LT30.03.2016
LV30.03.2016
MC30.03.2016
MT30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2018/01]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
IE30.03.2016
LT30.03.2016
LV30.03.2016
MC30.03.2016
MT30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/40]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
IE30.03.2016
LT30.03.2016
LV30.03.2016
MT30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/37]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
IE30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SI30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/07]AT30.03.2016
BE30.03.2016
CZ30.03.2016
DK30.03.2016
EE30.03.2016
FI30.03.2016
IE30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2017/03]AT30.03.2016
BE30.03.2016
CZ30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/51]AT30.03.2016
CZ30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
BE31.03.2016
GR01.07.2016
IS30.07.2016
PT01.08.2016
Former [2016/50]AT30.03.2016
CZ30.03.2016
EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
RO30.03.2016
SE30.03.2016
SK30.03.2016
BE31.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/49]EE30.03.2016
FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
PL30.03.2016
SE30.03.2016
BE31.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/48]FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
SE30.03.2016
BE31.03.2016
GR01.07.2016
IS30.07.2016
Former [2016/44]FI30.03.2016
LT30.03.2016
LV30.03.2016
NL30.03.2016
SE30.03.2016
BE31.03.2016
GR01.07.2016
Former [2016/39]FI30.03.2016
LT30.03.2016
LV30.03.2016
SE30.03.2016
BE31.03.2016
GR01.07.2016
Former [2016/36]FI30.03.2016
LT30.03.2016
BE31.03.2016
GR01.07.2016
Former [2016/35]FI30.03.2016
GR01.07.2016
Documents cited:Search[A]WO2005013901  (ISIS PHARMACEUTICALS INC [US], et al) [A] 1-15 * page 11 - page 13 * * page 41 - page 43 * * page 23, line 17 - line 27 * * page 75 - page 89 * * page 120; sequence 30 * * pages 131,134; sequences 214,313 *;
 [A]WO2005061710  (SANTARIS PHARMA AS [DK], et al) [A] 1-15 * the whole document *;
 [A]  - KRÜTZFELD, J. ET AL., "Silencing of microRNAs in vivo with 'antagomirs'.", NATURE, (200512), vol. 438, no. 7068, ISSN 0028-0836, pages 685 - 689, XP002376647 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/nature04303
 [A]  - JOPLING C ET AL., "Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA", SCIENCE, (200509), vol. 309, no. 5740, ISSN 0036-8075, pages 1577 - 1581, XP009109384 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1126/science.1113329
 [A]  - JEPSEN JAN STENVANG ET AL, "Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology", OLIGONUCLEOTIDES, (2004), vol. 14, no. 2, ISSN 1545-4576, pages 130 - 146, XP002395137 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1089/1545457041526317
 [A]  - BRENNECKE JULIUS ET AL, "Principles of microRNA-target recognition.", PLOS BIOLOGY, (200503), vol. 3, no. 3, ISSN 1545-7885, pages E85/0404 - E85/0418, XP002395136 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1371/journal.pbio.0030085
by applicantWO9914226
 WO0056746
 WO0056748
 WO0125248
 WO0228875
 EP1222309
 WO03006475
 WO03029459
 WO03095467
 US2005182005
 US2005227934
 WO2005098029
 US2005261218
 WO2006069584
    - BOUTLA ET AL., NUCLEIC ACIDS RESEARCH, (2003), vol. 31, pages 4973 - 4980
    - CHAN ET AL., CANCER RESEARCH, (2005), vol. 65, no. 14, pages 6029 - 6033
    - LECELLIER ET AL., SCIENCE, (2005), vol. 308, pages 557 - 560
    - NAGUIBNEVA ET AL., NATURE CELL BIOLOGY, (2006), vol. 8, no. 3, pages 278 - 84
    - DASS CR, J PHARM PHARMACOL, (2002), vol. 54, no. 1, pages 3 - 27
    - D. S. PEDERSEN; C. ROSENBOHM; T. KOCH, "Preparation of LNA Phosphoramidites", SYNTHESIS, (2002), vol. 6, pages 802 - 808
    - HUTTON, NAR, (1977), vol. 4, no. 10, pages 3537 - 3555
    - DR. B. JANSEN, "Section of experimental Oncology, Molecular Pharmacology", DEPARTMENT OF CLINICAL PHARMACOLOGY
    - HEID ET AL., "Real time quantitative PCR", GENOME RESEARCH, (1996), vol. 6, pages 986 - 994
    - CHAN ET AL., CANCER RESEARCH, (2005), vol. 65, no. 14, page 6029
    - IORIO ET AL., CANCER RESEARCH, (2005), vol. 65, no. 16, page 7065
    - ABELSON, J.F. ET AL., SCIENCE, (2005), vol. 310, pages 317 - 20
    - BARTEL, D.P., CELL, (2004), vol. 116, pages 281 - 297
    - BOEHM, M.; SLACK, F., SCIENCE, (2005), vol. 310, pages 1954 - 7
    - BRENNECKE, J. ET AL., CELL, (2003), vol. 113, pages 25 - 36
    - CALIN, G.A. ET AL., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, pages 15524 - 15529
    - CALIN, G. A. ET AL., PROC. NATL. ACAD. SCI.U.S.A., (2004), vol. 101, pages 2999 - 3004
    - CALIN, G.A. ET AL., N. ENGL. J. MED., (2005), vol. 353, pages 1793 - 801
    - CHAN, J.A. ET AL., CANCER RES., (2005), vol. 65, pages 6029 - 33
    - CHEN, C.Z. ET AL., SCIENCE, (2004), vol. 303, pages 83 - 86
    - EIS, P.S. ET AL., PROC NATL ACAD SCI USA., (2005), vol. 102, pages 3627 - 32
    - GIRALDEZ, A.J. ET AL., SCIENCE, (2005), vol. 308, pages 833 - 838
    - GRIFFITHS-JONES, S. ET AL., NUCLEIC ACIDS RES., (2004), vol. 32, pages D109 - D111
    - GRIFFITHS-JONES, S. ET AL., NUCLEIC ACIDS RES., (2006), vol. 34, pages D140 - 4
    - HE, L. ET AL., NATURE, (2005), vol. 435, pages 828 - 833
    - HORNSTEIN, E. ET AL., NATURE, (2005), vol. 438, pages 671 - 4
    - HUTVAGNER, G. ET AL., SCIENCE, (2001), vol. 293, pages 834 - 838
    - HUTVÁGNER, G. ET AL., PLOS BIOLOGY, (2004), vol. 2, pages 1 - 11
    - IORIO, M.V. ET AL., CANCER RES., (2005), vol. 65, pages 7065 - 70
    - JIN, P. ET AL., NAT CELL BIOL., (2004), vol. 6, pages 1048 - 53
    - JOHNSON, S.M. ET AL., CELL, (2005), vol. 120, pages 635 - 647
    - JOPLING, C.L. ET AL., SCIENCE, (2005), vol. 309, pages 1577 - 81
    - KETTING, R.F. ET AL., GENES DEV., (2001), vol. 15, pages 2654 - 2659
    - KWON, C. ET AL., PROC NATL ACAD SCI U S A., (2005), vol. 102, pages 18986 - 91
    - LANDTHALER, M. ET AL., CURR. BIOL., (2004), vol. 14, pages 2162 - 2167
    - LEAMAN, D. ET AL., CELL, (2005), vol. 121, pages 1097 - 108
    - LEE, Y. ET AL., NATURE, (2003), vol. 425, pages 415 - 419
    - LI, X.; CARTHEW, R.W., CELL, (2005), vol. 123, pages 1267 - 77
    - LU. J. ET AL., NATURE, (2005), vol. 435, pages 834 - 838
    - MICHAEL, M.Z. ET AL., MOL. CANCER RES., (2003), vol. 1, pages 882 - 891
    - NELSON, P. ET AL., TIBS, (2003), vol. 28, pages 534 - 540
    - PAUSHKIN, S. ET AL., CURR.OPIN.CELL BIOL., (2002), vol. 14, pages 305 - 312
    - POY, M.N. ET AL., NATURE, (2004), vol. 432, pages 226 - 230
    - WIENHOLDS, E. ET AL., SCIENCE, (2005), vol. 309, pages 310 - 311
    - YEKTA, S. ET AL., SCIENCE, (2004), vol. 304, pages 594 - 596
    - ZHAO, Y. ET AL., NATURE, (2005), vol. 436, pages 214 - 220
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.